Abstract: Objective: To evaluate the safety and efficacy of secukinumab in the treatment of the patients with psoriasis. Methods: The patients with moderate to severe plaque psoriasis and generalized pustular psoriasis were selected and treated with secukinumab 300 mg, once a week for 5 weeks, then 300 mg every four weeks for at least 4 weeks. The psoriasis area and severity index (PASI) in the plaque psoriasis patients and PSS score in the generalized pustular psoriasis patient were assessed before treatment and at week one, four, and eight of the treatment. Results: Six patients with plaque psoriasis and one patient with generalized pustular psoriasis were treated with secukinumab. Out of the 6 patients with plaque psoriasis, PASI 75 was achieved in all patients, PASI 90 was achieved in 3 patients, and PSS 2 was achieved at week 4 after the treatment. The PASI 100 was achieved in all plaque psoriasis patients and PSS 0 was achieved in the pustular psoriasis patient at week 8 after the treatment. All patients had no serious adverse drug reactions such as severe infection or malignancy. Conclusion: Secukinumab is effective and less adverse reactions for treating moderate to severe psoriasis.

Key words: secukinumab, plaque psoriasis, pustular psoriasis